Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 28 out of 100. Risk factors

Topic: Risk, prevention and care in population studies

The primary pharmacy system and health support pharmacy system were established in 2016. However, local pharmacies need to get closer to the community. To this end, each pharmacy is making efforts to contribute locally. Here, we introduce various initiatives in our region. Akakabe Pharmacy has 66 stores in Osaka Prefecture, mainly in the northeastern part of Osaka, where the elderly population is growing. We are implementing a dominant strategy: cooperation with the city and administration is strong, and we hold many related events directed towards the public. For example, two thousand participants gathered in an event sponsored by the city aimed at the improvement of beauty and health. At such events, participants can easily consult with pharmacists. Dispensing pharmacy stores-pharmacies that combine the features of a convenience store with care consulting services-were established in 2016. Care consultations are potentially highly advantageous to the users. In the consultation space of a pharmacy, a care worker conducts various events every month, such as on dementia prevention, body composition measurement, and more. We believe that this type of combined pharmacy and convenience store has the potential to become a regional comprehensive care center. We intend to share the possibility of a new pharmacy system, centered on this pharmacy/store/consultation model, as a basis to revamp the pharmacy industry.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Kuriyama, T., Shiromukai, K., Masui, R., Kitakoshi, W., & Matsuyama, N. (2019). The Pharmacy Combining Convenience Store with Care Consulting Services. YAKUGAKU ZASSHI. https://doi.org/10.1248/yakushi.18-00172-4

Vancouver

Kuriyama T, Shiromukai K, Masui R, Kitakoshi W, Matsuyama N. The Pharmacy Combining Convenience Store with Care Consulting Services. YAKUGAKU ZASSHI. 2019. doi:10.1248/yakushi.18-00172-4. PMID: 30930382.

BibTeX

@article{kuriyama2019-30930382,
  author  = {Kuriyama, Taisuke and Shiromukai, Kunihiko and Masui, Ryota and Kitakoshi, Wakako and Matsuyama, Noriaki},
  title   = {{The Pharmacy Combining Convenience Store with Care Consulting Services}},
  journal = {YAKUGAKU ZASSHI},
  year    = {2019},
  doi     = {10.1248/yakushi.18-00172-4},
  pmid    = {30930382},
  url     = {https://doi.org/10.1248/yakushi.18-00172-4}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

Key findings

Why it matters

This paper describes pharmacies in Japan that combine convenience store features with care consulting services, where care workers hold monthly events including on dementia prevention. It is a description of a service model and does not report evidence that this model prevents or treats dementia.

Study details

How this study scored 28/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 0 of 4; Study design 0 of 12; Strength of evidence 1 of 5; Peer-review validation 10 of 10; How recent 2 of 5; Sample size 0 of 4; Effect reported 0 of 3; Studied in people 0 of 3; Randomised / blinded 0 of 2; Times cited 1 of 7; Citations per year 0 of 5; Impact for its field and year 1 of 6; Cited by studies here 0 of 6; Still being cited 0 of 4; Senior author's track record left out, no data; Institution's track record left out, no data; Multi-centre collaboration 0 of 3; Indexed in PubMed 2 of 2; Free to read 2 of 2. 26 of the 93 points it could be judged on, which is 28 of 100. Total 28 of 100.26 of the 93 points we could judge = 28 of 100

Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomised / blinded because the record does not state it. We have no data on senior author's track record and institution's track record, so those were left out: it earned 26 of the 93 points we could judge it on, which is 28 out of 100.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (YAKUGAKU ZASSHI)
Journal's citation record 0 / 4 YAKUGAKU ZASSHI: journal h-index 62 (OpenAlex, 2026-10-29)
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 1 / 5 Rated “low” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 2 / 5 2019 — within 10 year(s) of the newest study here
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 0 / 3 Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomised / blinded 0 / 2 No randomisation or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 1 / 7 Cited 2 times (OpenAlex, 2026-10-10)
Citations per year 0 / 5 0.2 citations a year over 9 year(s) since 2019
Impact for its field and year 1 / 6 Cited 0.4× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 0 / 6 No other study in this library cites it
Still being cited 0 / 4 Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record — / 4 OpenAlex's profile for last-listed author Noriaki Matsuyama holds only 1 work(s), too few to judge a track record — left out of this score
Institution's track record — / 3 No institution listed in OpenAlex — left out of this score
Multi-centre collaboration 0 / 3 OpenAlex lists 0 institution(s) in 0 countries — scores zero (affiliation lists can be incomplete)
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 30930382)
Free to read 2 / 2 Free to read
Points 26 / 93 Scored on 18 of 20 parts. We have no data for the rest, so they are left out: 26 of the 93 points we could judge it on is 28 out of 100.
Total 28 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Related studies in Risk factors

Also in Risk factors

356 studies in the library are filed under Risk factors with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Risk factors hub.

Similar studies

More on Risk factors

See all studies in Risk factors →